Results 101 to 110 of about 19,412 (203)

First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review

Respirology Case Reports, Volume 14, Issue 9, September 2026.
A 45‐year‐old male with STRN–ALK‐positive lung adenocarcinoma and brain metastases achieved a significant and durable response to first‐line lorlatinib. Together with our literature review of 15 previously reported cases, this case supports further evaluation of lorlatinib as a first‐line treatment option for patients harbouring this rare ALK fusion ...
Masaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta   +4 more
wiley   +1 more source

Delayed Occurrence of Lung Cancer Leptomeningeal Metastasis and Era‐Associated Post‐LM Survival: A 14‐Year Single‐Center Cohort Study

Thoracic Cancer, Volume 17, Issue 17, September 2026.
In 201 cytology‐confirmed lung cancer LM cases, the modern era was associated with later LM diagnosis but no significant unadjusted improvement in post‐LM survival. Paired tissue‐CSF profiling identified actionable driver discordance in 8.75%, supporting CSF testing and improved CNS‐penetrant, molecularly matched therapies.
Xiaoxing Gao, Jie Gao, Qiuyue Ye, Chen Wei, Qing Zhou, Xiaoyan Liu, Minjiang Chen, Jing Zhao, Hanping Wang, Xiaoyan Si, Wei Zhong, Yan Xu, Mengzhao Wang   +12 more
wiley   +1 more source

Hypoxia-induced exosomal LUCAT1 promotes osimertinib resistance in lung adenocarcinoma by stabilizing c-MET

Cell Death and Disease
Osimertinib resistance poses a major challenge in treating advanced EGFR-mutant lung adenocarcinoma (LUAD). Exosomes, key mediators of intercellular communication, may contribute to drug resistance, but their specific role in osimertinib resistance ...
Jianting Du, Bin Zheng, Jiekun Qian, Guanglei Huang, Wenjie Yuan, Renjie Huang, Xian Gong, Guobing Xu, Bixing Zhao, Xiaolong Liu, Yingchao Wang, Zhang Yang, Chun Chen   +12 more
doaj   +1 more source

Central Nervous System Activity of Lazertinib in EGFR‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01

Thoracic Cancer, Volume 17, Issue 17, September 2026.
This pooled analysis of two Phase II trials included 72 patients with EGFR‐mutated NSCLC and CNS involvement after prior EGFR TKI exposure. Lazertinib achieved an intracranial ORR of 50.0%, with median intracranial PFS and OS of 15.2 and 17.8 months, respectively, supporting meaningful CNS activity in this later‐line setting.
Dong Hyun Kim, Min Hee Hong, Hyun Ae Jung, Tae Min Kim, Chang Gon Kim, Hee Kyung Ahn, Youngjoo Lee, Yu Jung Kim, Miso Kim, Jeonghwan Youk, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Dong‐Wan Kim, Myung‐Ju Ahn, Yoon Ji Choi, Sun Min Lim, Jin Hyoung Kang, Bhumsuk Keam, Hye Ryun Kim   +19 more
wiley   +1 more source

Potential interactions between traditional Chinese medicine and osimertinib: a Case Report

Frontiers in Pharmacology
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and ...
Min Zhang, Huiwen Ma, Wanyi Chen, Zhongzhen Yuan   +3 more
doaj   +1 more source

Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr‐Mutant Lung Cancer Mouse Model

Cancer Science, Volume 117, Issue 9, Page 2426-2442, September 2026.
Using an immunocompetent mouse model of Egfr Ex19del‐driven lung cancer, we found that osimertinib‐resistant tumors acquired Egfr V804F, the murine counterpart of human EGFR V802F. Afatinib, but not osimertinib, suppressed phosphorylation of EGFR and overcame V804F‐mediated resistance, providing a preclinical rationale for biomarker‐guided therapy ...
Takaaki Tanaka, Masato Fujitani, Masataka Taoka, Iwao Shimomura, Sachi Okawa, Shunta Mori, Tadahiro Kuribayashi, Jun Nishimura, Tomoka Nishimura, Ayako Morita, Naofumi Hara, Kiichiro Ninomiya, Go Makimoto, Hisao Higo, Kammei Rai, Eiki Ichihara, Shuta Tomida, Katsuyuki Hotta, Yosuke Togashi, Yoshinobu Maeda, Katsuyuki Kiura, Ryohei Katayama, Kadoaki Ohashi   +22 more
wiley   +1 more source

Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB–IIIA Non‐Small‐Cell Lung Cancer: Phase 2 neoSCORE Trial

Cancer Science, Volume 117, Issue 9, Page 2509-2520, September 2026.
Kaplan–Meier survival curves comparing two‐cycle versus three‐cycle neoadjuvant sintilimab plus chemotherapy. (A) Disease‐free survival (DFS). (B) Overall survival (OS). CI, confidence interval; HR, hazard ratio; NR, not reached. ABSTRACT The optimal number of neoadjuvant chemoimmunotherapy cycles for resectable non‐small cell lung cancer (NSCLC ...
Miner Shao, Jie Yao, Lufeng Zhao, Ling Zhu, Baizhou Li, Lili Li, Bangyi Zhou, Yixin Zhang, Huiying Liu, Xiaoke Chen, Zuqun Wu, Zexin Chen, Junqiang Fan, Fuming Qiu   +13 more
wiley   +1 more source

Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐Yl) Derivatives as EGFR Inhibitors Targeting EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S in NSCLC

Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.
Rational Design, Synthesis, Biological Evaluation, and In Silico Investigation of N‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting Wild‐Type and Mutant EGFR in NSCLC. ABSTRACT Non‐small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor ...
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Manjushree BV, Anguraj Moulishankar, Viney Chawla, Pooja A. Chawla   +6 more
wiley   +1 more source

Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer

Cancer Treatment and Research Communications
Resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor, remains a key challenge in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
Kevin M. Levine, Natalie F. Uy, Ted A. Gooley, Jenna Voutsinas, Micah Tratt, Keith D. Eaton, Rafael Santana-Davila, Alice H. Berger, Christina S. Baik   +8 more
doaj   +1 more source

Discovery of Potent EGFR Inhibitors for Del19 and L858R/T790M Mutants Through Structure‐Based Virtual Screening and Biological Evaluation

Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.
XJ2‐2 overcomes NSCLC by blocking EGFR‑driven AKT/ERK cascades. ABSTRACT Epidermal growth factor receptor (EGFR) mutation‐mediated drug resistance represents a major clinical challenge in the treatment of non‐small cell lung cancer (NSCLC). In this study, the lead compound XJ2‐2 was identified through structure‐based virtual screening.
Ting Xu, Yuchen Zhao, Mengfei Chen, Lijuan Zuo, Hanshuang Cai, Yuguo Liu, Chuanfeng Liu, Jing Shi   +7 more
wiley   +1 more source